Aravive (ARAV) Stock Price, News & Analysis

Company Overview

Aravive, Inc., a clinical-stage biopharmaceutical company, develops transformative treatments for life-threatening diseases, including cancer and fibrosis in the United States. Its lead product candidate is batiraxcept, an ultrahigh-affinity, decoy protein that targets the GAS6-AXL signaling pathway, which is in Phase III clinical trial for the treatment of platinum- resistant recurrent ovarian cancer; and in Phase Ib/II clinical trial for the treatment of clear cell renal cell carcinoma and pancreatic adenocarcinoma. The company also develops AVB-S6, a soluble Fc-fusion protein to block the activation of the GAS6-AXL signaling pathway. It has a license and collaboration agreement with WuXi Biologics (Hong Kong) Limited to identify and develop novel high-affinity bispecific antibodies targeting cancer and fibrosis; and license agreement with 3D Medicines Inc. to develop products that contain batiraxcept as the sole drug substance for the treatment of human oncological diseases in mainland China, Taiwan, Hong Kong, and Macau. The company was formerly known as Versartis, Inc. and changed its name to Aravive, Inc. in October 2018. Aravive, Inc. was incorporated in 2008 and is headquartered in Houston, Texas.

Key Stats

• Today's Range: $0.04 to $0.04
• 50-Day Range: $0.04 to $0.04
• 52-Week Range: $0.04 to $2.46
• Volume: N/A
• Average Volume: N/A
• Market Capitalization: $2.95 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

ARAV Stock Analysis - Frequently Asked Questions

How have ARAV shares performed this year?

Aravive's stock was trading at $0.0401 on January 1st, 2025. Since then, ARAV shares have increased by 0.0% and is now trading at $0.0401.
View the best growth stocks for 2025 here.

How were Aravive's earnings last quarter?

Aravive, Inc. (NASDAQ:ARAV) issued its quarterly earnings results on Wednesday, October, 27th. The company reported ($0.53) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.46) by $0.07. The business earned $2.41 million during the quarter, compared to analyst estimates of $2.36 million.

How do I buy shares of Aravive?

Shares of ARAV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Aravive own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Aravive investors own include NVIDIA (NVDA), CymaBay Therapeutics (CBAY), Broadcom (AVGO), General Electric (GE), Advanced Micro Devices (AMD), CrowdStrike (CRWD) and Meta Platforms (META).

Company Calendar

• Last Earnings: 10/27/2021
• Today: 4/04/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:ARAV
• CIK: 1513818
• Web: www.aravive.com
• Phone: (936) 355-1910
• Fax: N/A
• Employees: 20
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: $6.99 million
• Price / Sales: 0.42
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 73,563,000
• Free Float: 29,131,000
• Market Cap: $2.95 million
• Optionable: No Data
• Beta: 2.19